The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
The real-world evidence Flatiron's record system collects "is a key ingredient to accelerate the development of, and access to, new cancer treatments."
David Ebersman is perfectly suited for the maelstrom to come when the social-media giant's IPO hits the market.
